Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term 5-fluorouracil. Found 23 abstracts

no pagination
Meropol NJ, Feng Y, Grem JL, Mulcahy MF, Catalano PJ, Kauh JS, Hall MJ, Saltzman JN, George TJ, Zangmeister J, Chiorean EG, Cheema PS, O'Dwyer PJ, Benson AB. Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer. 2018 Feb 15;124(4):688-97.   PMCID: PMC6226304
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. Colon Cancer. Journal of the National Comprehensive Cancer Network. 2009 Sep;7(8):778-831.   PMCID: no NIH - Practice Guideline
Gold HT, Hall MJ, Blinder V, Schackman BR. Cost Effectiveness of Pharmacogenetic Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Before Irinotecan Administration for Metastatic Colorectal Cancer. Cancer. 2009 Sep;115(17):3858-67.   PMCID: PMC2853177
Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. Journal of Clinical Oncology. 2005 Jul;23(19):4330-7.
Cohen SJ, Dobelbower Jr R, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, Haller DG. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. International Journal of Radiation Oncology Biology Physics. 2005 Jan;62(5):1345-50.
Damjanov N, Meropol NJ. Oral therapy for colorectal cancer: How to choose. Oncology-New York. 2000 Jun;14(6):799-807.
Ho DH, Covington W, Brown N, Lin SN, Pazdur R, Huo YY, Creaven PJ, Rustum YM, Meropol NJ, Lassere Y, Kuritani J, Hayakawa T. Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. Cancer Chemotherapy and Pharmacology. 2000 Nov;46(5):351-6.
Meropol NJ, Rustum YM, Creaven PJ, Blumenson LE, Frank C. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: A potential role for growth factor as mucosal protectant. Cancer Investigation. 1999 Jan;17(1):1-9.
Berlin JD, Propert KJ, Trump D, Wilding G, Hudes G, Glick J, Burch P, Keller A, Loehrer P. 5-fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer - An Eastern Cooperative Oncology Group phase II study (E1889). American Journal of Clinical Oncology-Cancer Clinical Trials. 1998 Apr;21(2):171-6.
Bunn PA, Vokes EE, Langer CJ, Schiller JH. An update on North American randomized studies in non-small cell lung cancer. Seminars in Oncology. 1998 Aug;25(4):2-10.
Langer CJ, Schaebler D, Sauter E, DeMaria D, Johnson C, Reilly DM, Clark J, Leighton J, Aks C, Litwin S, Ridge JA. Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 1998 Aug;20(5):385-91.
Meropol NJ. Oral fluoropyrimidines in the treatment of colorectal cancer. European Journal of Cancer. 1998 Sep;34(10):1509-13.
Meropol NJ, Sonnichsen DS, Birkhofer MJ, Ferreira I, Noel D. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Cancer Chemotherapy and Pharmacology. 1998 Mar;43(3):221-6.
Stevenson JP, Scher RM, Kosierowski R, Fox SC, Simmonds M, Yao KS, Green F, Broom C, Fields SZ, Krebs JB, O'Dwyer PJ. Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. European Journal of Cancer. 1998 Aug;34(9):1358-62.
Witte RS, Ryan LM, Schutt AJ, Carbone PP, Engstrom PF. PALA versus streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma. Investigational New Drugs. 1998 Jan;16(4):315-8.
Gonen O, MurphyBoesch J, Li CW, PadavicShaller K, Negendank WG, Brown TR. Simultaneous 3D NMR spectroscopy of proton-decoupled fluorine and phosphorus in human liver during 5-fluorouracil chemotherapy. Magnetic Resonance in Medicine. 1997 Feb;37(2):164-9.
Hageboutros A, Hudes GR, Brennan J, Green F, Hoffman J, LaCreta FP, Colofiore J, Martin DS, Ozols RF, Odwyer PJ. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L- aspartate and 6-methylmercaptopurine ribonucleoside. Cancer Chemotherapy and Pharmacology. 1996 Jan;37(3):229-34.
Langer CJ, Hageboutros A, Kloth DD, Roby D, Shaer AH. Acute encephalopathy attributed to 5-FU. Pharmacotherapy. 1996 Mar;16(2):311-3.
Li CW, Gonen O. Simultaneous 3D NMR spectroscopy of fluorine and phosphorus in human liver during 5-fluorouracil chemotherapy. Magnetic Resonance in Medicine. 1996 Jun;35(6):841-7.
Coia L, Hoffman J, Scher R, Weese J, Solin L, Weiner L, Eisenberg B, Paul A, Hanks G. Preoperative Chemoradiation for Adenocarcinoma of the Pancreas and Duodenum. International Journal of Radiation Oncology Biology Physics. 1994 Aug 30;30(1):161-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term 5-fluorouracil

5-fluorouracil chemotherapy cancer leucovorin fluorouracil trial colorectal cancer therapy cisplatin infusion pharmacokinetics phase-ii trial uracil tegafur modulation biochemical modulation tumor 5-ethynyluracil 776c85 irinotecan phosphorus colorectal-carcinoma mitomycin-c pancreatic cancer surgery infusion fluorouracil radiation carcinoma adenocarcinoma magnetic-resonance spectroscopy oxaliplatin anti-tumor activity UFT neutropenia doxorubicin plasma pancreatectomy combination phase-ii fluorouracil plus leucovorin continuous Tumors diastereoisomers lymph-node micrometastases folinic acid randomized-trial methylmercaptopurine riboside Ftorafur(tegafur) fluorouracil failure 1- ifosfamide colorectal-cancer fam predictive factors ethynyluracil 3D chemical shift imaging phase-iii trial southwest-oncology-group metabolism tomography ampulla topotecan carboplatin Oncology oncology-group thymidylate synthase GM-CSF oxaliplatin-based S-1 pancreatic carcinoma pancreaticoduodenectomy PALA Toxicity adriamycin uft duodenal cancer high-dose NCCN Clinical Practice Guidelines Chemotherapy toxicity cancer chemotherapy morbidity recovery prostate cancer phase-i levamisole ugt1a1-asterisk-28 genotype radiation-therapy prognostic factors Adenocarcinoma of the pancreas liver riboside Locally advanced capecitabine Patient treatment ftorafur diarrhea cancer staging p53 growth-factor receptor folfiri Radiotherapy advanced squamous cell carcinoma of the phosphonacetyl-L-aspartate beam irradiation External beam radiotherapy pancreas carcinoma xenografts leukemia group-b Diseases colorectal invivo calcium leucovorin Pancreatic cancer unresectable liver metastases b- bevacizumab mitomycin C chemoradiation recombinant interferon alpha drug development leukoencephalopathy radiotherapy phase II trial continuous-infusion 5-fluorouracil thymidine phosphorylase randomized streptozotocin combination treatment 5-FU n-(phosphonacetyl)-l-aspartic acid spectra regimen granulocyte-macrophage colony-stimulating aspartate-transcarbamylase vinblastine pharmacology adjuvant dihydropyrimidine dehydrogenase methotrexate head and neck MeCCNU continuous-infusion fluorouracil infusion neoplasm staging quality prednisone UGT1A1 genotype testing-irinotecan-cost-effectiveness analysis-colorectal cancer (2-tetrahydrofuryl)-5-fluorouracil overexpression fluorine
Last updated on Wednesday, March 04, 2020